OncRef

Clinical Trial: NCT05933265

Study of LP-184 in Patients With Advanced Solid Tumors

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 1

Lead Sponsor:Lantern Pharma Inc.
Information Provided By:Lantern Pharma Inc.
Last Update Posted:2026-05-04

Study Overview

Brief Summary

The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard therapy is available. The secondary objectives are to characterize the PK of LP-184 and its metabolites in plasma and assess clinical activity of LP-184.

Participants will receive LP-184 infusion during Day 1 and Day 8 of each 21-day cycle, for a minimum of two cycles. Patients will be monitored for safety, PK, and clinical activity

Official Title

A Phase 1/2 Dose Escalation and Cohort Expansion Study of LP-184 in Patients With Advanced or Metastatic Solid Tumors

Conditions

Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer, NSCLC, Pancreatic Adenocarcinoma, DDR Gene Mutation

Intervention / Treatment

  • Drug: LP-184
  • Drug: Olaparib
  • Drug: Nivolumab & Ipilimumab

Other Study ID Numbers

  • LTRN184-1AST23-1

Start Date (Actual)

2023-06-09

Primary Completion Date (Estimated)

2026-07-28

Study Completion Date (Estimated)

2026-07-28

Enrollment (Actual)

64

Study Type

Interventional

Phase

Phase 1, Phase 2